Renovaro BioSciences, GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer
LOS ANGELES, CA - (NewMediaWire) - August 10, 2023 - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and private companies to optimize investor awareness and recognition.
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer
Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, and GEDi Cube Intl Ltd. have executed a binding, exclusive letter of intent ("LOI"). The LOI outlines the merge of a subsidiary with GEDi Cube, a cutting-edge health AI company. According to the announcement, the resulting company would focus on accelerating the diagnosis of cancer and other diseases, as well as enhancing treatment effectiveness, discovering new therapies and expanding access to life-saving technologies. According to the announcement, Renovaro Biosciences officials are confident that joining forces with GEDi Cube could "enhance the efficacy of upcoming trials and speed up the discovery of novel treatment approaches." Renovaro is currently involved in studying pancreatic cancer and potential treatments; the company also plans to include other solid tumors with short life-expectancy in studies that are slated to start by mid-2024.
"I have been privileged to lead life sciences groups at Intel, Oracle and, most recently, NVIDIA," said GEDi Cube International Ltd. CEO Craig Rhodes in the press release. "But GEDi Cube's remarkably innovative technology developed over nearly a decade has already validated earlier diagnoses of lung cancer in humans at a leading university hospital and created the technology for 12 additional cancers, including pancreatic and breast cancer, which is very inspiring and exciting. We are rapidly expanding our technologies to include other cancers and diseases. I believe that uniting with Renovaro Biosciences' potential solid tumor therapies is not merely synergistic. It could also create a multiplier effect to expedite diagnosis, improve treatment outcomes and discover, in silico, new therapies to improve many lives."
To view the full press release, visit https://ibn.fm/hskUn
About Renovaro BioSciences Inc.
Renovaro BioSciences is an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company's advanced cell, gene and immunotherapy techniques are designed to reinvigorate the body's natural tumor-fighting mechanisms. For more information about the company, visit www.RenovaroBio.com.
About IBN
IBN has introduced 50+ distinct investor-focused brands over the last 15+ years and has leveraged these unique brands to amass a collective audience of millions of social media followers. In conjunction with 5,000+ syndication partnerships, IBN's broad-based investor-facing brands help fulfill the diverse demands and needs of our rapidly growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, harnessing the energy and experience of our team of specialized experts to exceed the expectations of each of our client-partners.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
